# PF-07104091 as a Single Agent and in Combination Therapy

> **NCT04553133** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 157 (actual)

## Conditions studied

- Small Cell Lung Cancer
- Ovarian Cancer
- Breast Cancer

## Interventions

- **DRUG:** PF-07104091 monotherapy dose escalation
- **DRUG:** PF-07104091 + palbociclib + fulvestrant
- **DRUG:** PF-07104091 + palbociclib + letrozole
- **DRUG:** PF-07104091 monotherapy dose expansion (ovarian)
- **DRUG:** PF-07104091 monotherapy dose expansion (SCLC)
- **DRUG:** PF-07104091 + Fulvestrant (post CDK4/6)
- **DRUG:** PF-0704091 + Fulvestrant (post CDK4/6)

## Key facts

- **NCT ID:** NCT04553133
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-16
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04553133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04553133, "PF-07104091 as a Single Agent and in Combination Therapy". Retrieved via AI Analytics 2026-05-20 from https://api.ai-analytics.org/clinical/NCT04553133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*